CureVac N.V. has announced a purchase agreement with BioNTech SE, dated June 12, 2025. The agreement outlines the terms and conditions of the acquisition, including actions related to equity awards, the extraordinary general meeting, and post-offer reorganization. Both companies have agreed to issue a joint press release announcing the execution of this agreement. The announcement, made by CureVac N.V., marks a significant development in the collaboration between these two companies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059879), on June 16, 2025, and is solely responsible for the information contained therein.